Navigation Links
Myelofibrosis Pipeline Therapeutics Reviewed for H2 2015 in New Research
Date:11/12/2015

PUNE, Maharashtra, November 12, 2015 /PRNewswire/ --

Myelofibrosis - Pipeline Review, H2 2015 helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products, enhance decision making capabilities and create effective counter strategies to gain competitive advantage.

Complete H2 2015 report on Myelofibrosis Pipeline Review spread across 189 pages, analyzing 19 companies, 25 drug profiles and supported with 36 tables and 13 figures is now available at http://www.rnrmarketresearch.com/myelofibrosis-pipeline-review-h2-2015-market-report.html .

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

The report provides a snapshot of the global therapeutic landscape of Myelofibrosis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects. A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources summarizing all the dormant and discontinued pipeline projects. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Top Companies covered in this report Acceleron Pharma, Inc., Bristol-Myers Squibb Company, Celgene Corporation, CTI BioPharma Corp., Galena Biopharma, Inc., Gilead Sciences, Inc., Incyte Corporation, Italfarmaco S.p.A., Johnson & Johnson, JW Pharmaceutical Corporation, KaloBios Pharmaceuticals, Inc., Nippon Shinyaku Co., Ltd., Novartis AG, Onconova Therapeutics, Inc., Pfizer Inc., PharmaEssentia Corporation, Promedior, Inc., Stemline Therapeutics, Inc. and Threshold Pharmaceuticals, Inc. Drug Profiles discussed in this report are anagrelide hydrochloride CR, BMS-911543, buparlisib hydrochloride, CWP-291, erismodegib, evofosfamide, givinostat, glasdegib, Hu8F4, idelalisib, imetelstat sodium, INCB-39110, KB-004, LCL-161, momelotinib dihydrochloride, NS-018, pacritinib, pixantrone dimaleate, pomalidomide, PRM-151, rigosertib sodium, ropeginterferon ALFA-2B, simtuzumab, SL-401 and sotatercept. Order a copy of Myelofibrosis - Pipeline Review, H2 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=427341 .

Another newly published report on Liposarcoma - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Liposarcoma and enlists all their major and minor projects. Complete report on Liposarcoma Pipeline Review is available at http://www.rnrmarketresearch.com/liposarcoma-pipeline-review-h2-2015-market-report.html .

Explore more reports on Cancer Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed


'/>"/>
SOURCE RnR Market Research
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
2. CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
3. CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
4. CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
5. CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis
6. FDA Grants Fast Track Designation to CTI BioPharmas Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
7. Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting
8. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
9. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
10. Therapeutic Pipeline of Portal Hypertension Reviewed for 2015 in New Market Research Report
11. Anthrax - Pipeline Review, H2 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):